Analyst Reco. Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Real-time Estimate Tradegate Other stock markets 12:01:49 2024-06-28 pm EDT			5-day change	1st Jan Change
228.3 ^EUR	-1.17%		+59.42%	+31.55%

04:24pm	UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	MT
Jun. 27	Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating	10:24am	MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating	Jun. 27	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating	Jun. 27	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	Jun. 26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	Jun. 26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	Jun. 26	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	Jun. 26	MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating	Jun. 25	MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating	Jun. 25	MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating	Jun. 25	MT
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating	Jun. 25	MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating	Jun. 25	MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating	Jun. 25	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating	Jun. 25	MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	Jun. 25
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	Jun. 03	MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	May. 07	MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	Apr. 08
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Equities

DUL

US02043Q1076

Analyst Reco.

Filters